Evidence map›Paper›PMID 34047805›Full record

ArticleNeuroradiology2021

Longitudinal structural and perfusion MRI enhanced by machine learning outperforms standalone modalities and radiological expertise in high-grade glioma surveillance.

Loizos Siakallis, Carole H Sudre, Paul Mulholland, Naomi Fersht, Jeremy Rees, Laurens Topff, Steffi Thust, Rolf Jager, M Jorge Cardoso, Jasmina Panovska-Griffiths and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Neuroradiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Loizos SiakallisLysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK. Loizos.siakallis@nhs.net.ORCID http://orcid.org/0000-0003-3057-0568
Carole H SudreTranslational Imaging Group, Centre for Medical Image Computing, University College London , London, UK.
Paul MulhollandDepartment of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
Naomi FershtDepartment of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
Jeremy ReesDepartment of Brain Repair and Rehabilitation, UCL Institute of Neurology, London, UK.
Laurens TopffDepartment of Radiology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Steffi ThustLysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK.
Rolf JagerLysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK.
M Jorge CardosoTranslational Imaging Group, Centre for Medical Image Computing, University College London , London, UK.
Jasmina Panovska-GriffithsInstitute for Global Health, University College London, London, UK.
Sotirios BisdasLysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK.
National Hospital for Neurology and Neurosurgery · GBUniversity College London · GBUniversity College London Hospitals NHS Foundation Trust · GBThe Netherlands Cancer Institute · NLUniversity of Oxford · GB

Funding

Medical Research Council MR/M009106/1
6 · The paper itself

Abstract

purposeSurveillance of patients with high-grade glioma (HGG) and identification of disease progression remain a major challenge in neurooncology. This study aimed to develop a support vector machine (SVM) classifier, employing combined longitudinal structural and perfusion MRI studies, to classify between stable disease, pseudoprogression and progressive disease (3-class problem).

methodsStudy participants were separated into two groups: group I (total cohort: 64 patients) with a single DSC time point and group II (19 patients) with longitudinal DSC time points (2-3). We retrospectively analysed 269 structural MRI and 92 dynamic susceptibility contrast perfusion (DSC) MRI scans. The SVM classifier was trained using all available MRI studies for each group. Classification accuracy was assessed for different feature dataset and time point combinations and compared to radiologists' classifications.

resultsSVM classification based on combined perfusion and structural features outperformed radiologists' classification across all groups. For the identification of progressive disease, use of combined features and longitudinal DSC time points improved classification performance (lowest error rate 1.6%). Optimal performance was observed in group II (multiple time points) with SVM sensitivity/specificity/accuracy of 100/91.67/94.7% (first time point analysis) and 85.71/100/94.7% (longitudinal analysis), compared to 60/78/68% and 70/90/84.2% for the respective radiologist classifications. In group I (single time point), the SVM classifier also outperformed radiologists' classifications with sensitivity/specificity/accuracy of 86.49/75.00/81.53% (SVM) compared to 75.7/68.9/73.84% (radiologists).

conclusionOur results indicate that utilisation of a machine learning (SVM) classifier based on analysis of longitudinal perfusion time points and combined structural and perfusion features significantly enhances classification outcome (p value= 0.0001).

Indexed as

Brain NeoplasmsGliomaHumansMachine LearningMagnetic Resonance ImagingPerfusionRetrospective StudiesGlioblastoma (GB)GliomaMachine learningPerfusionRadiomics

Identifiers

PMID34047805
PMCPMC8589799
OpenAlexW3165650936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.